UTBT gđ I, phẫu thuật rất “mạnh tay”: cắt tử cung, 2 phần phụ,
mạc nối lớn, chưa hết! còn phải hóa trị hỗ trợ sau khi mổ. Tại sao?
- Lý do thứ nhất: hóa trị sau mổ sẽ làm tăng
PFS sau 5 năm thêm 20%.
Dựa trên nghiên cứu của Italian Interregional
Cooperative Group (IICG)
Nghiên cứu này chia những bn UTBT gđ I đã phẫu thuật tận gốc
thành 2 nhóm: nhóm 1 điều trị với cisplatin 50mg/m2 mỗi 4 tuần, nhóm 2 không điều
trị. Kết quả PFS sau 5 năm của nhóm 1 so với nhóm 2 là 83% sv 63%.
- Lý do thứ hai: hóa trị sau mổ sẽ làm tăng tỉ lệ sống còn(SR)
sau 5 năm thêm 8%.
EORTC đã thực hiện nghiên cứu mang tên –Adjuvant
Treatment in Ovarian Neoplasms (ACTION) và ICON cũng đã thực hiện 1 nghiên cứu tương tự. Hai nghiên cứu này được cùng kết hợp số liệu để đi đến kết luận tỉ lệ sống còn 5 năm của nhóm hóa trị sau mổ so với nhóm chỉ theo dõi là (74% vs 82%; 95% CI, 2%–12%).
the European Organisation for Research and Treatment of Cancer
(EORTC)–Adjuvant Treatment in Ovarian Neoplasms (ACTION) trial and the
International Collaborative on Ovarian Neoplasms (ICON) 1 trial were
combined and reported - See more at:
http://www.cancernetwork.com/cancer-management/ovarian/page/0/3#sthash.JdOLqHrH.dpuf
the European Organisation for Research and Treatment of Cancer
(EORTC)–Adjuvant Treatment in Ovarian Neoplasms (ACTION) trial and the
International Collaborative on Ovarian Neoplasms (ICON) 1 trial were
combined and reported - See more at:
http://www.cancernetwork.com/cancer-management/ovarian/page/0/3#sthash.JdOLqHrH.dpuf
the
European Organisation for Research and Treatment of Cancer
(EORTC)–Adjuvant Treatment in Ovarian Neoplasms (ACTION) trial and the
International Collaborative on Ovarian Neoplasms (ICON) 1 trial were
combined and reported. An absolute 5-year survival rate improvement of
8% was reported for those who received immediate chemotherapy compared
with reserving chemotherapy for those who relapsed (74% vs 82%; 95% CI,
2%–12%).
- See more at:
http://www.cancernetwork.com/cancer-management/ovarian/page/0/3#sthash.JdOLqHrH.dpuf
the
European Organisation for Research and Treatment of Cancer
(EORTC)–Adjuvant Treatment in Ovarian Neoplasms (ACTION) trial and the
International Collaborative on Ovarian Neoplasms (ICON) 1 trial were
combined and reported. An absolute 5-year survival rate improvement of
8% was reported for those who received immediate chemotherapy compared
with reserving chemotherapy for those who relapsed (74% vs 82%; 95% CI,
2%–12%).
- See more at:
http://www.cancernetwork.com/cancer-management/ovarian/page/0/3#sthash.JdOLqHrH.dpuf
the
European Organisation for Research and Treatment of Cancer
(EORTC)–Adjuvant Treatment in Ovarian Neoplasms (ACTION) trial and the
International Collaborative on Ovarian Neoplasms (ICON) 1 trial were
combined and reported. An absolute 5-year survival rate improvement of
8% was reported for those who received immediate chemotherapy compared
with reserving chemotherapy for those who relapsed (74% vs 82%; 95% CI,
2%–12%).
- See more at:
http://www.cancernetwork.com/cancer-management/ovarian/page/0/3#sthash.JdOLqHrH.dpuf
the
European Organisation for Research and Treatment of Cancer
(EORTC)–Adjuvant Treatment in Ovarian Neoplasms (ACTION) trial and the
International Collaborative on Ovarian Neoplasms (ICON) 1 trial were
combined and reported. An absolute 5-year survival rate improvement of
8% was reported for those who received immediate chemotherapy compared
with reserving chemotherapy for those who relapsed (74% vs 82%; 95% CI,
2%–12%).
- See more at:
http://www.cancernetwork.com/cancer-management/ovarian/page/0/3#sthash.JdOLqHrH.dpuf
the
European Organisation for Research and Treatment of Cancer
(EORTC)–Adjuvant Treatment in Ovarian Neoplasms (ACTION) trial and the
International Collaborative on Ovarian Neoplasms (ICON) 1 trial were
combined and reported. An absolute 5-year survival rate improvement of
8% was reported for those who received immediate chemotherapy compared
with reserving chemotherapy for those who relapsed (74% vs 82%; 95% CI,
2%–12%).
- See more at:
http://www.cancernetwork.com/cancer-management/ovarian/page/0/3#sthash.JdOLqHrH.dpuf
No comments:
Post a Comment